Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 6912345...102030...Last »

The End of the Road: NovaDel Pharma to Dissolve

After taking more than a year to sell off its insomnia medication ZolipiMist to Amherst Pharmaceuticals, NovaDel Pharma has dissolved the company.

Read More »

Thermo Fisher did not infringe genetic-test patent

The U.S. Supreme Court cleared a subsidiary of biotech company Thermo Fisher Scientific Inc. of infringing a genetic-testing kit patent held by Promega Corp.

Read More »

Pfizer, Celgene, Eli Lilly, Merck & Co. CEOs and Other Execs Send Letter Supporting GOP Tax Plan

Chief executive officers from more 16 large manufacturing companies – including pharma leaders from Celgene, Dow Chemical, Eli Lilly, Merck and Pfizer – penned a letter to Congressional leaders in support of a Republican-backed tax reform plan.

Read More »

Serial Investor Carl Icahn Takes Stake in Bristol-Myers Squibb, Stock Jumps

Hours after Bristol-Myers Squibb announced a $2 billion stock buyback plan, billionaire investor Carl Icahn snapped up a “large stake” of BMS stock, which sent shares soaring.

Read More »

U.S. top court rejects patent licensing appeal

The U.S. Supreme Court turned away an appeal of a Maryland state court jury verdict ordering Boston Scientific Corp. to pay $308 million to a patent licensor.

Read More »

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016

For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.

Read More »

Interest in Nordic Nanovector’s NHL treatment

Norwegian biotech newcomer Nordic Nanovector, which seeks ways to treat blood-related cancers, says other companies are showing interest in buying the firm.

Read More »

Takeda Splits Off Its Consumer Healthcare Biz

Takeda Pharmaceutical has entered into an agreement to transfer its Japan Consumer Healthcare Business Unit to Takeda Consumer Healthcare.

Read More »

Swiss Biotech Santhera Opens Up 20 Employee Shop in Massachusetts, Has Plans to Grow

Switzerland-based Santhera Pharmaceuticals, the maker of a treatment for Duchenne Muscular Dystrophy, opened its first office in the United States.

Read More »

UnitedHealth sued by U.S. government over Medicare charges

The U.S. Justice Department joined a whistleblower lawsuit against UnitedHealth Group Inc. that claims the country’s largest health insurer and its units and affiliates overcharged Medicare hundreds of millions of dollars, a law firm representing the whistleblower said.

Read More »

Trump, Republicans set timeframe for introducing Obamacare replacement

President Donald Trump and Republicans in Congress said they will unveil plans to repeal and replace Obamacare, providing a timeframe for a legislative goal they have struggled with for weeks.

Read More »

Amygdala Acquires GS-6637 from Gilead

Amygdala Neurosciences has agreed to acquire Gilead’s GS-6637, a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions.

Read More »

Anthem sues Cigna to block deal termination

Anthem filed a lawsuit to block Cigna from terminating their proposed $54 billion deal, which would have created the largest U.S. health insurer by membership.

Read More »

Integra to buy J&J’s Codman neurosurgery biz

Medical device maker Integra LifeSciences Holdings Corp. said it would buy Johnson & Johnson’s Codman neurosurgery business for $1.05 billion in cash.

Read More »

Special Feature – Agenda 2017: Growing Up

Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai

Read More »

Special Feature: Interesting times for pharma sales reps

Despite the general anxiety over the impact of President Trump’s policies, when it comes to pharmaceutical sales forces, little of what he does will actually affect pharma sales-force strategies. The trends that are continuing to play out are declining rep access, the size of pharma sales forces, and the struggle with the concept of key account management, as well as trying to figure out how reps should be compensated.

Read More »

U.S. trends in aggregate spend, disclosure, and transparency: Writing the next chapter on transparency initiatives

QuintilesIMS’ annual survey of pharmaceutical and device manufacturers was initiated in 2009 – when only a handful of U.S. states required disclosure of certain healthcare practitioner payments. Since then, of course, state, federal and global requirements have continually evolved and expanded. Our latest survey findings, which reflect responses from 112 manufacturers, underscore that while the bar keeps getting higher, manufacturers’ confidence and sophistication are also on the rise.

Read More »

Launching a drug on all cylinders – winning with digital

“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).

Read More »

Merrimack names former Sanofi Genzyme executive CEO

The fully integrated biopharma company Merrimack appointed a new president and CEO: Richard Peters, M.D., Ph.D.. He additionally became a member of Merrimack Pharmaceuticals’ board of directors.

Read More »

New head of Americas Pharmaceuticals business for Bayer

Bayer appointed Dr. Carsten Brunn as president of its Pharmaceuticals business in the Americas, comprising the United States, Canada, Central America, and Latin America. In this role, Dr. Brunn reports to Dieter Weinand, member of the board of management of Bayer AG and president of the Pharmaceutical division.

Read More »

Page 1 of 6912345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2016 Focus: Trump, Turing, New Marketing Ventures and more!


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation